BBS-Bioactive Bone Substitutes
0.08
EUR
+14.94 %
BONEH
First North Finland
Medical Equipment & Services
Health Care
3,936 following
+14.94%
-15.07%
-72.97%
-81.78%
-76.86%
-82.68%
-81.13%
-96.03%
-94.65%
-97.21%
www.bbs-artebone.fi
BBS-Bioactive Bone Substitutes is a medical technology company. The company designs, develops and constructs biological implants for patients with bone defects and healing problems. The company's solutions are resold under the Artebone brand and are based on tricalcium phosphate (TCP) and bone protein, which stimulates the bone healing process. The company was founded in 2003 and is headquartered in Oulu.
P/E (adj.) (24e)
-0.59
EV/EBIT (adj.) (24e)
-2.31
P/B (24e)
0.72
Dividend yield-% (24e)
-
Target price
0.30 EUR
Recommendation
Reduce
Updated
29.9.2024
First North Finland
BONEH
Daily low / high price
0.07 / 0.094
EUR
Market cap
2.12M EUR
Turnover
12.2K EUR
Volume
155K
Business risk
Valuation risk
Current
Previous
Income statement
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | 2.0 | 4.1 |
| growth-% | 150.0 % | 5,605.7 % | 246.3 % | 109.8 % | ||||
| EBITDA | -2.4 | -2.3 | -2.7 | -3.1 | -3.1 | -3.4 | -3.6 | -1.6 |
| EBIT (adj.) | -2.6 | -2.6 | -3.0 | -3.4 | -3.3 | -4.3 | -4.5 | -2.5 |
| EBIT | -2.6 | -2.6 | -3.0 | -3.4 | -3.3 | -4.3 | -4.5 | -2.5 |
| Profit before taxes | -2.7 | -2.8 | -3.1 | -3.5 | -3.5 | -4.6 | -4.8 | -2.8 |
| Net income | -2.7 | -2.8 | -3.1 | -3.5 | -3.5 | -4.6 | -4.8 | -2.8 |
| EPS (adj.) | -0.42 | -0.40 | -0.32 | -0.18 | -0.14 | -0.18 | -0.19 | -0.11 |
| growth-% | ||||||||
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio |
Profitability and return on capital
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| EBITDA-% | -60,775.0 % | -58,500.0 % | -68,150.0 % | -78,738.0 % | -31,165.1 % | -603.2 % | -183.8 % | -38.7 % |
| EBIT-% (adj.) | -66,125.0 % | -64,275.0 % | -73,775.0 % | -84,150.0 % | -33,165.1 % | -758.6 % | -229.7 % | -60.0 % |
| EBIT-% | -66,125.0 % | -64,275.0 % | -73,775.0 % | -84,150.0 % | -33,165.1 % | -758.6 % | -229.7 % | -60.0 % |
| ROE | -59.6 % | -57.0 % | -78.2 % | -74.2 % | -87.3 % | -804.4 % | 116.5 % | 35.1 % |
| ROI | -24.4 % | -23.1 % | -28.5 % | -31.6 % | -33.9 % | -49.6 % | -53.4 % | -28.8 % |
Valuation
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Share price (EUR) | 4.76 | 2.19 | 1.27 | 0.47 | 0.08 | 0.08 | 0.08 | 0.08 |
| Shares | 6.6 | 7.0 | 9.7 | 19.3 | 25.8 | 25.8 | 25.8 | 25.8 |
| Market cap | 31.3 | 15.3 | 12.3 | 9.1 | 2.1 | 2.1 | 2.1 | 2.1 |
| Enterprise value | 34.0 | 20.4 | 17.2 | 12.6 | 7.6 | 12.1 | 17.0 | 19.9 |
| EV/S | 8,507.9 | 5,108.6 | 4,295.3 | 3,156.0 | 764.9 | 21.2 | 8.6 | 4.8 |
| EV/EBITDA | - | - | - | - | - | - | - | - |
| EV/EBIT (adj.) | - | - | - | - | - | - | - | - |
| EV/EBIT | - | - | - | - | - | - | - | - |
| P/E (adj.) | - | - | - | - | - | - | - | - |
| P/E | - | - | - | - | - | - | - | - |
| P/B | 5.1 | 4.2 | 2.9 | 1.8 | 0.7 | - | - | - |
| P/S | 7,820.1 | 3,822.4 | 3,070.5 | 2,272.2 | 206.0 | 3.6 | 1.0 | 0.5 |
| Dividend yield | ||||||||
| Equity ratio | 48.0 % | 34.6 % | 40.0 % | 48.2 % | 32.1 % | -20.4 % | -77.2 % | -106.9 % |
| Gearing ratio | 45.2 % | 141.6 % | 114.7 % | 69.1 % | 194.1 % | -580.6 % | -227.2 % | -190.9 % |
Quarter data
| Q3/23 | Q4/23 | 2023 | Q1/24 | Q2/24 | Q3/24e | Q4/24e | 2024e | Q1/25e | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | |||||
| EBITDA | -1.7 | -3.1 | -1.5 | -1.6 | -3.1 | ||||
| EBIT | -1.8 | -3.4 | -1.6 | -1.7 | -3.3 | ||||
| Profit before taxes | -1.8 | -3.5 | -1.7 | -1.8 | -3.5 | ||||
| Net income | -1.8 | -3.5 | -1.7 | -1.8 | -3.5 |
ShowingAll content types
BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd
BBS-Bioactive Bone Substitutes Plc – Insider information: The company updates the status of the CE marking process
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools